Αρχειοθήκη ιστολογίου

Δευτέρα 16 Ιουλίου 2018

New biologics in the treatment of urticaria

Purpose of review Symptomatic management of chronic spontaneous urticaria (CSU) basically depends on second-generation H1 antihistamines and omalizumab. Omalizumab is a game changer in the management, but still there is a need for new targets and new biologics targeting new pathways in the treatment which will provide long-lasting remission, which will be given orally and which will be cheaper. This review will focus on new biologics that are underway of production or are already under use for different disorders but could be beneficial for the treatment of Chronic urticaria. Recent findings In this review, the treatment targets are classified according to the cells which are involved in the pathogenesis of CSU. Those are mast cells/basophils, B cells, T cells and eosinophils. The treatments that are under clinical trials for CSU are anti-IgE treatments such as ligelizumab, molecules targeting intracellular signaling pathways such as spleen tyrosine kinase inhibitors, surface inhibitory molecules such as siglec-8, anti-IL-1s such as canakinumab, Bruton kinase (BTK) inhibitors such as GDC-0853 and anti-IL-5s such as benralizumab and mepolizumab. Summary The ongoing clinical trials on new targets of treatment hold new hopes not only for a better care of the disease but also a better understanding of the pathomechanisms lying underneath. Correspondence to Emek Kocatürk, Department of Dermatology, Okmeydanı Training and Research Hospital, Darulaceze Caddesi, Sisli, Istanbul, Turkey. Tel: +90 2123146300; e-mail: emekozgur@yahoo.com Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2uAOqk9

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου